10575534.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptasxm1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new

```
                  custom IPC display formats
 NEWS 32  JAN 28  MARPAT searching enhanced
 NEWS 33  JAN 28  USGENE now provides USPTO sequence data within 3 days
                  of publication
 NEWS 34  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
 NEWS 35  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements

 NEWS EXPRESS  19 SEPTEMBER 2007:  CURRENT WINDOWS VERSION IS V8.2,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 22:58:55 ON 05 FEB 2008

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 22:59:17 ON 05 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 FEB 2008  HIGHEST RN 1001463-85-9
DICTIONARY FILE UPDATES:   4 FEB 2008  HIGHEST RN 1001463-85-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html
```

```
=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.46       0.67

FILE 'REGISTRY' ENTERED AT 22:59:51 ON 05 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    4 FEB 2008  HIGHEST RN 1001463-85-9
DICTIONARY FILE UPDATES:   4 FEB 2008  HIGHEST RN 1001463-85-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10575534.str
```





chain nodes :
10 11 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
4-10 6-11 8-13
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 4-10 5-6 6-11 7-8 8-9 8-13

G1:O,S

10575534.trn

G2:O,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:CLASS

L1   STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1   STR



G1 O,S
G2 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sam
SAMPLE SEARCH INITIATED 23:00:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   26 TO ITERATE

100.0% PROCESSED   26 ITERATIONS   25 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 215 TO   825
PROJECTED ANSWERS: 200 TO   800

L2   25 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 23:01:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   548 TO ITERATE

100.0% PROCESSED   548 ITERATIONS   530 ANSWERS
SEARCH TIME: 00.00.01

L3   530 SEA SSS FUL L1

```
=> fil capl
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.82     179.49

FILE 'CAPLUS' ENTERED AT 23:01:17 ON 05 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 5 Feb 2008  VOL 148 ISS 6
FILE LAST UPDATED: 4 Feb 2008  (20080204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4          18 L3

=> d l4 ibib hitstr abs 1-18
```

L4 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:477981 CAPLUS
DOCUMENT NUMBER: 147:95621
TITLE: SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction
AUTHOR(S): Hunt, Fraser; Austin, Caroline; Austin, Rupert; Bonnert, Roger; Cage, Peter; Christie, Jadeen; Christie, Mark; Dixon, Clare; Hill, Steven; Jewell, Robert; Martin, Ian; Robinson, David; Willis, Paul
CORPORATE SOURCE: AstraZeneca R&D Charnwood, Loughborough, LE11 5RH, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(10), 2731-2734
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:95621
IT 259101-56-9
RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of thiazolo[4,5-d]pyrimidines as CXCR2 antagonists)
RN 259101-56-9 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



IT 259101-53-6P 259101-71-8P 259101-81-0P
333743-03-6P 333743-41-2P 333743-47-8P
333743-72-9P 333743-87-6P 354565-82-5P
354565-88-1P 676345-70-3P 942408-06-2P
942408-08-4P 942408-09-5P 942408-10-8P
942408-11-9P 942408-12-0P 942408-13-1P
942408-14-2P 942408-16-4P 942408-17-5P
942408-19-7P 942408-20-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of thiazolo[4,5-d]pyrimidines as CXCR2 antagonists)
RN 259101-53-6 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-71-8 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-81-0 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333743-03-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-41-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-47-8 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 333743-72-9 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-87-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-82-5 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 354565-88-1 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 676345-70-3 CAPLUS
CN 1,3-Butanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-06-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-08-4 CAPLUS
CN 1-Propanol, 2-[[2-(cyclopropylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-09-5 CAPLUS
CN 1,3-Propanediol, 2-[[2-(cyclopropylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 942408-10-8 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-11-9 CAPLUS
CN 1-Butanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-12-0 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-(methylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-13-1 CAPLUS
CN 1-Propanol, 2-[[2-(diethylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-14-2 CAPLUS
CN 1,3-Propanediol, 2-[[2-(diethylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 942408-16-4 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-fluorophenyl)methyl]thio]thiazolo[4,5-

d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-17-5 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-19-7 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-chloro-2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 942408-20-0 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 259101-61-6 333742-99-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolo[4,5-d]pyrimidines as CXCR2 antagonists)
RN 259101-61-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 333742-99-7 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 333743-71-8P 354565-89-2P 944703-70-2P
944703-83-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolo[4,5-d]pyrimidines as CXCR2 antagonists)

RN 333743-71-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-89-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 944703-70-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[(2-hydroxy-1,1-dimethylethyl)amino]- (CA INDEX NAME)



RN 944703-83-7 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB As part of a Lead Optimization program to identify small mol. antagonists of the human CXCR2 receptor, a series of substituted thiazolo[4,5-d]pyrimidines was prepared via the application of a novel tandem

displacement reaction. E.g., thiazolo[4,5-d]pyrimidine I was prepared from II via a tandem amination.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1066530 CAPLUS
DOCUMENT NUMBER: 145:397542
TITLE: Preparation of 5,7-disubstituted thiazolo[4,5-d]pyrimidin-2(3H)-ones as chemokine CX3CR1 receptor antagonists.
INVENTOR(S): Nordvall, Gunnar; Ray, Colin; Rein, Tobias; Sohn, Daniel
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 74pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006107257	A1	20061012	WO 2006-SE398	20060403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006231835	A1	20061012	AU 2006-231835	20060403
CA 2604016	A1	20061012	CA 2006-2604016	20060403
EP 1869055	A1	20071226	EP 2006-717077	20060403
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN 2007DN07177	A	20071005	IN 2007-DN7177	20070918
KR 2008004484	A	20080109	KR 2007-722814	20071005
PRIORITY APPLN. INFO.:			SE 2005-768 A	20050406
			WO 2006-SE398 W	20060403

OTHER SOURCE(S): MARPAT 145:397542
IT 911715-50-9P 911715-51-0P 911715-52-1P
911715-53-2P 911715-54-3P 911715-55-4P
911715-56-5P 911715-57-6P 911715-58-7P
911715-59-8P 911715-60-1P 911715-61-2P
911715-62-3P 911715-63-4P 911715-64-5P
911715-65-6P 911715-66-7P 911715-67-8P
911715-68-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of thiazolopyrimidinones as chemokine CX3CR1 receptor antagonists)
RN 911715-50-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[(1R)-1-[3-(methylsulfonyl)phenyl]ethyl]thio]- (CA

INDEX NAME)

Absolute stereochemistry.



RN 911715-51-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[1-[3-(trifluoromethyl)phenyl]ethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-52-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)butyl]amino]-5-[[(1S)-1-phenylethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-53-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[(1S)-1-[3-(methylsulfonyl)phenyl]ethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-54-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[1-[2-(trifluoromethyl)phenyl]ethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-55-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)butyl]amino]-5-[[(1S)-1-[3-(methylsulfonyl)phenyl]ethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-56-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(1-phenylethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-57-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[(1R)-1-phenylethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-58-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[(1S)-1-phenylethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-59-8 CAPLUS
CN Benzonitrile, 3-[(1S)-1-[[2,3-dihydro-7-[[(1R)-1-(hydroxymethyl)butyl]amino]-2-oxothiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-60-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[1-[3-(methylsulfonyl)phenyl]ethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-61-2 CAPLUS
CN Benzamide, 3-[(1S)-1-[[2,3-dihydro-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-2-oxothiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-62-3 CAPLUS
CN Benzamide, 3-[(1R)-1-[[2,3-dihydro-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-2-oxothiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-63-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(1-phenylpropyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-64-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-65-6 CAPLUS
CN Benzonitrile, 3-[(1S)-1-[[2,3-dihydro-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-2-oxothiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-66-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-3-fluoro-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-67-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]-7-[[(1R)-1-(hydroxymethyl)butyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-68-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(1S)-1-(3-fluorophenyl)ethyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 463954-32-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolopyrimidinones as chemokine CX3CR1 receptor antagonists)
RN 463954-32-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 849943-17-5P 849943-46-0P 849943-47-1P
911715-71-4P 911715-73-6P 911715-74-7P
911715-76-9P 911715-77-0P 911715-81-6P
911715-83-8P 911715-84-9P 911715-86-1P
911715-87-2P 911715-89-4P 911715-90-7P
911715-92-9P 911715-94-1P 911715-96-3P
911716-01-3P 911716-03-5P 911716-04-6P
911716-06-8P 911716-10-4P 911716-12-6P
911716-13-7P 911716-15-9P 911716-17-1P
911716-19-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolopyrimidinones as chemokine CX3CR1 receptor antagonists)

RN 849943-17-5 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-46-0 CAPLUS
CN 1-Pentanol, 2,2'-[dithiobis[(2-methoxythiazolo[4,5-d]pyrimidine-5,7-diyl)imino]]bis[4-methyl-, (2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-47-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5,5'-dithiobis[7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-71-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1R)-1-[3-(methylsulfonyl)phenyl]ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-73-6 CAPLUS
CN 1-Pentanol, 2-[[2-methoxy-5-[[(1R)-1-[3-(methylsulfonyl)phenyl]ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-74-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-1-(hydroxymethyl)butyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-76-9 CAPLUS
CN 1-Pentanol, 2,2'-[dithiobis[(2-methoxythiazolo[4,5-d]pyrimidine-5,7-diyl)imino]]bis-, (2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-77-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5,5'-dithiobis[7-[[(1R)-1-(hydroxymethyl)butyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-81-6 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-[3-(methylsulfonyl)phenyl]ethyl]thio]th
iazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-83-8 CAPLUS
CN 1-Pentanol, 2-[[2-methoxy-5-[[(1S)-1-[3-(methylsulfonyl)phenyl]ethyl]thio]
thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-84-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(1-phenylethyl)thio]thiazolo[4,5-d]pyrimidin-7-
yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-86-1 CAPLUS
CN 1-Pentanol, 2-[[2-methoxy-5-[(1-phenylethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-87-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1R)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-89-4 CAPLUS
CN 1-Pentanol, 2-[[2-methoxy-5-[[(1R)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-90-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-92-9 CAPLUS
CN 1-Pentanol, 2-[[2-methoxy-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-94-1 CAPLUS
CN Benzonitrile, 3-[(1S)-1-[[2-amino-7-[[(1R)-1-(hydroxymethyl)butyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-96-3 CAPLUS
CN Benzonitrile, 3-[(1S)-1-[[7-[[(1R)-1-(hydroxymethyl)butyl]amino]-2-methoxythiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-01-3 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-03-5 CAPLUS
CN 1-Pentanol, 2-[[5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-04-6 CAPLUS
CN Benzonitrile, 3-[(1S)-1-[[2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-06-8 CAPLUS
CN Benzonitrile, 3-[(1S)-1-[[7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-2-methoxythiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-10-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-fluoro-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-12-6 CAPLUS
CN 1-Pentanol, 4-fluoro-2-[[5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-13-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-15-9 CAPLUS
CN 1-Pentanol, 2-[[5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-17-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-(3-fluorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-19-3 CAPLUS
CN 1-Pentanol, 2-[[5-[[(1S)-1-(3-fluorophenyl)ethyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



GI



I

AB Title compds. (I; R1 = Me, Et; R2 = H, 3-cyano, 2-CF3, 2-F, 3-F, 3-CONH2, 3-SO2Me; R3 = H; R4 = H, Me; R5 = H, F), were prepared Thus, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(1-phenylethyl)thio]thiazolo[4,5-d]pyrimidin-2(3H)-one [prepared in 67% yield from (2R)-2-[(2-amino-5-mercaptothiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol and (1-bromoethyl)benzene] showed antagonism at the CX3CR1 receptor with Ki = 1.3 nM.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1065985 CAPLUS
DOCUMENT NUMBER: 145:419167
TITLE: Preparation of 5-substituted 7-aminothiazolo[4,5-d]pyrimidines as chemokine CX3CR1 receptor antagonists.
INVENTOR(S): Nordvall, Gunnar; Ray, Colin; Rein, Tobias; Sohn, Daniel
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 56pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006107258	A1	20061012	WO 2006-SE399	20060403
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006231836	A1	20061012	AU 2006-231836	20060403
CA 2604017	A1	20061012	CA 2006-2604017	20060403
EP 1869056	A1	20071226	EP 2006-717078	20060403
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
IN 2007DN07181	A	20071005	IN 2007-DN7181	20070918
KR 2008004483	A	20080109	KR 2007-722813	20071005
PRIORITY APPLN. INFO.:			SE 2005-767 A	20050406
			WO 2006-SE399 W	20060403

OTHER SOURCE(S): MARPAT 145:419167
IT 911715-81-6P 911715-84-9P 911715-87-2P
911715-90-7P 911715-94-1P 911716-01-3P
911716-04-6P 911716-10-4P 911716-13-7P
911716-17-1P 911819-84-6P 911819-87-9P
911819-89-1P 911819-91-5P 911819-93-7P
911819-95-9P 911819-97-1P 911820-00-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of aminothiazolopyrimidines as chemokine CX3CR1
receptor antagonists)
RN 911715-81-6 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-[3-(methylsulfonyl)phenyl]ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-84-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(1-phenylethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-87-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1R)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-90-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-94-1 CAPLUS
CN Benzonitrile, 3-[(1S)-1-[[2-amino-7-[[(1R)-1-(hydroxymethyl)butyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-01-3 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-04-6 CAPLUS
CN Benzonitrile, 3-[(1S)-1-[[2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-10-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-fluoro-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-13-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-(2-fluorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911716-17-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-(3-fluorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911819-84-6 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911819-87-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(1-phenylpropyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911819-89-1 CAPLUS
CN Benzamide, 3-[1-[[2-amino-7-[[(1R)-1-(hydroxymethyl)-3-

methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 911819-91-5 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[1-[3-(trifluoromethyl)phenyl]ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911819-93-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(1-phenylethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911819-95-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[1-(2-chlorophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911819-97-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[1-(3-methoxyphenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911820-00-3 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(1S)-1-phenylethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-fluoro-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 463954-32-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aminothiazolopyrimidines as chemokine CX3CR1 receptor antagonists)
RN 463954-32-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 849942-77-4P 849942-84-3P 849943-17-5P
911715-74-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aminothiazolopyrimidines as chemokine CX3CR1 receptor antagonists)
RN 849942-77-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-84-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-17-5 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 911715-74-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-1-(hydroxymethyl)butyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



GI



I

AB Title compds. (I; R1 = Me, Et; R2 = H, 2-F, 2-Cl, 3-F, 3-OMe, 3-cyano, 3-CF3, 3-CONH2, 3-SO2Me; R3,R4 = H, Me; R5 = H, F), were prepared Thus, (2R)-2-[(2-amino-5-mercaptothiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-4-ol was coupled with (1-chloropropyl)benzene to give (2R)-2-[[2-amino-5-[(1-phenylpropyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol. The latter bound to CX3CR1 receptors with Ki = 3.1 nM.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1005627 CAPLUS
DOCUMENT NUMBER: 145:369821
TITLE: Screening for allosteric modulators of class A G protein-coupled receptors
INVENTOR(S): Grahames, Caroline; Mallinder, Philip; Mcintosh, Fraser; Tomkinson, Nicholas; Wright, Tracey
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 217pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006101439	A1	20060928	WO 2006-SE355	20060322
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1864136	A1	20071212	EP 2006-717040	20060322
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: SE 2005-668 A 20050323
WO 2006-SE355 W 20060322

IT 333742-45-3 333742-46-4 333742-63-5
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(screening for allosteric modulators of class A G protein-coupled receptors)
RN 333742-45-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-46-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-63-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(3-chloro-2-fluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



AB The present invention is based on the identification of a binding site for small mol. weight compds. on the intracellular side of CXCR2, a G protein-coupled receptor. Domain swap expts. and site-directed mutagenesis methods in conjunction with homol. modeling approach identify specific a domain (residues 304-326) and amino acids (Lys-320 in CXCR2 and Arg-310 in CXCR1) in mediating binding of inhibitors from different series of small mol. antagonists. Compds. binding CXCR2 at this cytoplasmic site inhibit the binding of interleukin-8 to CXCR2 at an extracellular site via an allosteric mechanism. By alignment and homol. modeling, the intracellular binding site is predicted to be present in all class A G protein-coupled receptors. The elucidation of this novel binding site facilitates designing or identifying specific and potent inhibitory small mol. compds. for therapeutic purposes, including and assays (such as competitive binding assays).

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:16623 CAPLUS
DOCUMENT NUMBER: 144:184021
TITLE: Hit-to-Lead studies: The discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists
AUTHOR(S): Baxter, Andrew; Cooper, Anne; Kinchin, Elizabeth; Moakes, Kerry; Unitt, John; Wallace, Alan
CORPORATE SOURCE: AstraZeneca R&D Charnwood, Loughborough, LE11 5RH, UK
SOURCE: Bioorg. Med. Chem. Lett. (2006), 16(4), 960-963
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 259100-40-8 259100-45-3 259100-69-1
259100-74-8 259101-51-4 259101-52-5
259101-53-6 259101-55-8 874963-36-7
874963-40-3
RL: PAC (Pharmacological activity); BIOL (Biological study)
(discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists)
RN 259100-40-8 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259100-45-3 CAPLUS
CN Ethanol, 2-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259100-69-1 CAPLUS
CN 1-Propanol, 3-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259100-74-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclopentyl-5-(pentylthio)- (CA INDEX NAME)



RN 259101-51-4 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-52-5 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-53-6 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-55-8 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 874963-36-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N,N-diethyl-5-(pentylthio)- (9CI)

(CA INDEX NAME)



RN 874963-40-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[(phenylmethyl)thio]- (CA INDEX NAME)



IT 259100-39-5 259101-56-9
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists)
RN 259100-39-5 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-56-9 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



GI



AB A Hit-to-Lead optimization program was carried out on a high throughput screening hit, the thiazolopyrimidine (I), resulting in the discovery of the potent, orally bioavailable CXCR2 antagonist II.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:547606 CAPLUS
DOCUMENT NUMBER: 143:78206
TITLE: Process for preparation of 5-difluorobenzylthio-7-aminothiazolo[4,5-d]pyrimidin-2(3H)-ones via protection and amination reactions.
INVENTOR(S): Butters, Michael; Wisedale, Richard; Thomson, Colin; Welham, Matthew James; Watts, Andrew
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056563	A2	20050623	WO 2004-GB5072	20041202
WO 2005056563	A3	20050825		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004296241	A1	20050623	AU 2004-296241	20041202
CA 2546719	A1	20050623	CA 2004-2546719	20041202
EP 1711505	A2	20061018	EP 2004-801262	20041202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1914213	A	20070214	CN 2004-80041445	20041202
BR 2004017300	A	20070306	BR 2004-17300	20041202
JP 2007513131	T	20070524	JP 2006-542009	20041202
IN 2006DN02941	A	20070803	IN 2006-DN2941	20060522
MX 2006PA06148	A	20060719	MX 2006-PA6148	20060531
NO 2006003111	A	20060905	NO 2006-3111	20060704
US 2007282103	A1	20071206	US 2007-581143	20070214
PRIORITY APPLN. INFO.:			GB 2003-28243 A	20031205
			WO 2004-GB5072 W	20041202

OTHER SOURCE(S): MARPAT 143:78206
IT 676345-23-6P 855476-56-1P 855476-57-2P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(claimed compound; preparation of difluorobenzylthioaminothiazolopyrimidinones via protection and amination reactions)
RN 676345-23-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 855476-56-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]-, monopotassium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● K

RN 855476-57-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monopotassium salt (9CI) (CA INDEX NAME)



● K

IT 855476-59-4P 855476-60-7P 855476-62-9P
855476-63-0P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of difluorobenzylthioaminothiazolopyrimidinones via protection and amination reactions)

RN 855476-59-4 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]-3-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 855476-60-7 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]-3-[2-(phenylsulfonyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 855476-62-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-3-[2-(phenylsulfonyl)ethyl]-7-[(2,2,5-trimethyl-1,3-dioxan-5-yl)amino]- (CA INDEX NAME)



RN 855476-63-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-3-[2-(phenylsulfonyl)ethyl]- (CA INDEX NAME)



IT 333742-48-6P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of difluorobenzylthioaminothiazolopyrimidinones via protection and amination reactions)
RN 333742-48-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II

AB Title compds. I [R1 = (substituted) carbocyclyl, alkyl, alkenyl, alkynyl, aryl, heteroaryl; R2, R3 = H, (substituted) alkyl, carbocyclyl, alkenyl, alkynyl], were prepared by treatment of precursors II (R1 as above; L =

leaving group; Q = H) with a protecting reagent to give I; (R1, L as above; Q = protecting group), treatment of the latter with HNR2R3 (R2, R3 as above), and deprotection. Thus, 7-chloro-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-2(3H)-one (preparation given) and p-TsOH in PhMe at 60° was treated with 3,4-dihydropyran over 1 h and maintained at 60° for 2 h. The mixture was cooled, stirred with aqueous NaHCO3 and then brine and the resulting solution was heated with THF, Na2CO3, and D-alaninol followed by heating at 60° for 11.5 h and at 65° for 24 h to give 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]-3-(tetrahydro-2H-pyran-2-yl)thiazolo[4,5-d]pyrimidin-2(3H)-one. The latter in MeCN/H2O/THF at 65° was treated with 1N HCl over 3 h to give 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-2(3H)-one.

L4 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:324167 CAPLUS
DOCUMENT NUMBER: 142:392432
TITLE: Preparation of new 2-substituted-4-aminothiazolo[4,5-d]pyrimidines and pteridinones useful as CX3CR1 chemokine receptor antagonists
INVENTOR(S): Nordvall, Gunnar; Rein, Tobias; Sohn, Daniel; Zemribo, Ronald
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005033115	A1	20050414	WO 2004-SE1421		20041005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004278276	A1	20050414	AU 2004-278276		20041005
AU 2004278276	B2	20071018			
CA 2541533	A1	20050414	CA 2004-2541533		20041005
EP 1675862	A1	20060705	EP 2004-775512		20041005
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR					
CN 1856499	A	20061101	CN 2004-80027529		20041005
BR 2004015050	A	20061128	BR 2004-15050		20041005
JP 2007507494	T	20070329	JP 2006-532235		20041005
MX 2006PA03792	A	20060614	MX 2006-PA3792		20060404
US 2007142386	A1	20070621	US 2006-575534		20060407
NO 2006002061	A	20060703	NO 2006-2061		20060508
PRIORITY APPLN. INFO.:			SE 2003-2666	A	20031007
			SE 2003-2667	A	20031007
			WO 2004-SE1421	W	20041005

OTHER SOURCE(S): CASREACT 142:392432; MARPAT 142:392432
IT 849942-71-8P, (2R)-2-[[2-Amino-5-(benzyloxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-73-0P, (2R)-2-[[2-Amino-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-74-1P, (2R)-2-[[2-Amino-5-(2-phenylethoxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-75-2P, (2R)-2-[[2-Amino-5-(2-phenoxyethoxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-76-3P, (2R)-2-[[2-Amino-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-79-6P, (2R)-2-[[2-Amino-5-[(4-chlorobenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-

methylpentan-1-ol 849942-80-9P, (2R)-2-[[2-Amino-5-[(3-chlorobenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-81-0P, (2R)-2-[[2-Amino-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-82-1P, (2R)-2-[[2-Amino-5-(benzyloxy)[1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-83-2P 849942-86-5P 849942-88-7P, (2R)-2-[[2-Amino-5-[[2-(2-bromophenyl)ethyl]sulfinyl][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-90-1P, (R)-2-[[2-Amino-5-[[2-(2-bromophenyl)ethyl]sulfinyl][1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849943-09-5P, 5-(Benzyloxy)-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-14-2P, 7-[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-15-3P, 7-[[(1R)-1-(Hydroxymethyl)-3-methylbutyl]amino]-5-(2-phenylethoxy)[1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-16-4P, 5-(Benzyloxy)-7-[[(1R)-1-(hydroxymethyl)butyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-22-2P, 7-[[(1R)-1-(Hydroxymethyl)butyl]amino]-5-[((1S)-1-phenylethyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-23-3P, N-[3-[[[7-[[(1R)-1-(Hydroxymethyl)butyl]amino]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl]oxy]methyl]phenyl]-N-methylmethanesulfonamide 849943-25-5P, N-[3-[[[7-[[(1R)-1-(Hydroxymethyl)-2-methylpropyl]amino]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl]oxy]methyl]phenyl]methanesulfonamide 849943-31-3P , 5-(Benzyloxy)-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-34-6P, 7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[(2-methylbenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-35-7P, 7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[(3-methylbenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-36-8P, 5-[(2-Chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-37-9P, 5-[(3-Chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-38-0P, 5-[(4-Chlorobenzyl)oxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-39-1P, 7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[(2-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-40-4P, 7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[(3-methoxybenzyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-41-5P, 4-[[[7-[[1-(Hydroxymethyl)cyclopentyl]amino]-2-oxo-2,3-dihydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl]oxy]methyl]benzonitrile 849943-42-6P, 7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-(1-phenylethoxy)thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-43-7P, 7-[[1-(Hydroxymethyl)cyclopentyl]amino]-5-[((1S)-1-phenylethyl)oxy][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-44-8P, 5-[[2-(3-Chlorophenyl)ethyl]sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-49-3P, 5-[[2-(2-Bromophenyl)ethyl]sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-51-7P, 5-[(2,3-Difluorobenzyl)sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-52-8P, 5-(Benzylsulfinyl)-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-55-1P, 5-[(2-Chlorobenzyl)sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-

one 849943-57-3P, 5-[(4-Chlorobenzyl)sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-59-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of new 2-substituted-4-amino-thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)

RN 849942-71-8 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-(phenylmethoxy)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-73-0 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(3-methoxyphenyl)methoxy]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-74-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-(2-phenylethoxy)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-75-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-(2-phenoxyethoxy)thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-76-3 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(2-methylphenyl)methoxy]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-79-6 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(4-chlorophenyl)methoxy]thiazolo[4,5-

d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-80-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(3-chlorophenyl)methoxy]thiazolo[4,5-
d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-81-0 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(2-methoxyphenyl)methoxy]thiazolo[4,5-
d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-82-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-(phenylmethoxy)thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-83-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(4-bromo-2-fluorophenyl)methyl]sulfinyl]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-86-5 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[2-(4-bromophenyl)ethyl]sulfinyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-88-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[2-(2-bromophenyl)ethyl]sulfinyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-90-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[2-(2-bromophenyl)ethyl]sulfinyl]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-09-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-(phenylmethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-14-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(3-methoxyphenyl)methoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-15-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-(2-phenylethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-16-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)butyl]amino]-5-(phenylmethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-22-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)butyl]amino]-5-[(1S)-1-phenylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-23-3 CAPLUS
CN Methanesulfonamide, N-[3-[[[2,3-dihydro-7-[[(1R)-1-(hydroxymethyl)butyl]amino]-2-oxothiazolo[4,5-d]pyrimidin-5-yl]oxy]methyl]phenyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-25-5 CAPLUS
CN Methanesulfonamide, N-[3-[[[2,3-dihydro-7-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-2-oxothiazolo[4,5-d]pyrimidin-5-yl]oxy]methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-31-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-(phenylmethoxy)- (CA INDEX NAME)



RN 849943-34-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(2-methylphenyl)methoxy]- (CA INDEX NAME)



RN 849943-35-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(3-methylphenyl)methoxy]- (CA INDEX NAME)



RN 849943-36-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(2-chlorophenyl)methoxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino]- (CA INDEX NAME)



RN 849943-37-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(3-chlorophenyl)methoxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino]- (CA INDEX NAME)



RN 849943-38-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(4-chlorophenyl)methoxy]-7-[[1-(hydroxymethyl)cyclopentyl]amino]- (CA INDEX NAME)



RN 849943-39-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(2-methoxyphenyl)methoxy]- (CA INDEX NAME)



RN 849943-40-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(3-methoxyphenyl)methoxy]- (CA INDEX NAME)



RN 849943-41-5 CAPLUS
CN Benzonitrile, 4-[[[2,3-dihydro-7-[[1-(hydroxymethyl)cyclopentyl]amino]-2-oxothiazolo[4,5-d]pyrimidin-5-yl]oxy]methyl]- (CA INDEX NAME)



RN 849943-42-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-(1-phenylethoxy)- (CA INDEX NAME)



RN 849943-43-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(1S)-1-phenylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-44-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[2-(3-chlorophenyl)ethyl]sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-49-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[2-(2-bromophenyl)ethyl]sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-51-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-52-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)sulfinyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-55-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2-chlorophenyl)methyl]sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-57-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(4-chlorophenyl)methyl]sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-59-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-[(phenylmethyl)sulfinyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 259101-09-2, (2R)-2-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 259101-69-4, (2R)-2-[[2-Amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 463954-32-7, (2R)-2-[(2-Amino-5-mercapto[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol 849943-27-7, (2R)-2-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methylbutan-1-ol
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of new 2-substituted-4-amino-thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)
RN 259101-09-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-69-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-32-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-27-7 CAPLUS

CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 463954-27-0P, [1-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]cyclopentyl]methanol 849942-72-9P, (2R)-2-[[2-Amino-5-(benzylsulfonyl)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-77-4P, (2R)-2-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-78-5P, (2R)-2-[[2-Amino-5-(benzylsulfonyl)[1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-84-3P, (2R)-2-[(2-Amino-5-mercapto[1,3]thiazolo[4,5-d]pyrimidin-7-yl)(methyl)amino]-4-methylpentan-1-ol 849942-85-4P, (2R)-2-[[2-Amino-5-[(4-bromo-2-fluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl](methyl)amino]-4-methylpentan-1-ol 849942-87-6P, (2R)-2-[[2-Amino-5-[[2-(4-bromophenyl)ethyl]thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849942-89-8P, (2R)-2-[[2-Amino-5-[[2-(2-bromophenyl)ethyl]thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-11-9P, (2R)-2-[[5-[(2,3-Difluorobenzyl)thio]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-13-1P, 5-[(2,3-Difluorobenzyl)sulfonyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-17-5P, (2R)-2-[[2-Amino-5-(benzylthio)[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentan-1-ol 849943-19-7P, (2R)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]pentan-1-ol 849943-20-0P, 5-(Benzylthio)-7-[[(1R)-1-(hydroxymethyl)butyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-21-1P, 5-(Benzylsulfonyl)-7-[[(1R)-1-(hydroxymethyl)butyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-28-8P, (2R)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methylbutan-1-ol 849943-30-2P, 5-(Benzylsulfonyl)-7-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-32-4P, 5-(Benzylthio)-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-33-5P, 5-(Benzylsulfonyl)-7-[[1-(hydroxymethyl)cyclopentyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-46-0P, (2R)-2-[[5-[7-[((1R)-1-Hydroxymethyl-3-methylbutyl)amino]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-5-yldisulfanyl]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-47-1P 849943-48-2P, 5-[[2-(3-Chlorophenyl)ethyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one

849943-50-6P, 5-[[2-(2-Bromophenyl)ethyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-53-9P, (2R)-2-[[5-(Benzylthio)-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol 849943-56-2P, 5-[(2-Chlorobenzyl)thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one 849943-58-4P, 5-[(4-Chlorobenzyl)thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of new 2-substituted-4-amino-thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)

RN 463954-27-0 CAPLUS
CN Cyclopentanemethanol, 1-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 849942-72-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-77-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-78-5 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-84-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-85-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(4-bromo-2-fluorophenyl)methyl]thio]thiazolo[4

,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-87-6 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[2-(4-bromophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849942-89-8 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[2-(2-bromophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-11-9 CAPLUS
CN 1-Pentanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-13-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]sulfonyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-17-5 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-19-7 CAPLUS
CN 1-Pentanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-20-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)butyl]amino]-

5-[(phenylmethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-21-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)butyl]amino]-5-[(phenylmethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-28-8 CAPLUS
CN 1-Butanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-30-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-[(phenylmethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-32-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)



RN 849943-33-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[1-(hydroxymethyl)cyclopentyl]amino]-5-[(phenylmethyl)sulfonyl]- (CA INDEX NAME)



RN 849943-46-0 CAPLUS
CN 1-Pentanol, 2,2'-[dithiobis[(2-methoxythiazolo[4,5-d]pyrimidine-5,7-diyl)imino]]bis[4-methyl-, (2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-47-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5,5'-dithiobis[7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-48-2 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[2-(3-chlorophenyl)ethyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-50-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[2-(2-bromophenyl)ethyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-53-9 CAPLUS
CN 1-Pentanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-56-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2-chlorophenyl)methyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-58-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(4-chlorophenyl)methyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 463954-11-2 849943-60-8 849943-61-9
RL: PRP (Properties)
(solubility comparison to ether analog; preparation of new 2-substituted-4-amino-
thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)
RN 463954-11-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-60-8 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(2-phenylethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-61-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[[(3-methoxyphenyl)methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



IT 849942-91-2P 849943-12-0P 849943-29-9P
849943-54-0P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(solubility comparison to ether analog; preparation of new 2-substituted-4-amino-
thiazolo[4,5-d]pyrimidines useful as CX3CR1 chemokine receptor antagonists)
RN 849942-91-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[2-(2-bromophenyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-12-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-29-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 849943-54-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



GI



AB There are disclosed 2-substituted-4-aminothiazolo[4,5-d]pyrimidines and pteridinones (shown as I; variables defined below; e.g. 5-(benzyloxy)-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo [4,5-d]pyrimidin-2(3H)-one (shown as II)) and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compns. comprising them and their use in therapy. I are CX3CR1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, atherosclerosis and pain. For I: A = 1,2-dihydro-2-oxo-3-R21pyrazine, 2-(R22R23N)thiazole, or 2-oxothiazoline; R1 and R2 = H, C1-8-alkyl, C2-8-alkenyl, C2-8-alkynyl or C3-7 saturated or partially unsatd. cycloalkyl; the latter 4 groups being optionally further substituted; R3 = C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl or C3-7 saturated or partially unsatd. cycloalkyl; X = O or S(O); R21 = H, CH2OR24, CH2NR24R25, CO2R24 or CONR24R25; R22 and R23 = H, C1-6-alkyl, C2-6-alkenyl or C3-7 saturated or partially unsatd. cycloalkyl; n = 0-2; R4-R20, R24, R25 = H or C1-6-alkyl; addnl. details are given in the claims. Methods of preparation are claimed and 49 example prepns. are included. For example, II was prepared in 5 steps (88, 88, 90, 82 and 16 % yields) starting from (2R)-2-[[2-amino-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol and involving intermediates (2R)-2-[[2-chloro-5-[(2,3-difluorobenzyl)thio][1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol, (2R)-2-[[5-[(2,3-difluorobenzyl)thio]-2-methoxy[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol, 5-[(2,3-difluorobenzyl)thio]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one and 5-[(2,3-difluorobenzyl)sulfonyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one. When tested in a ligand binding assay, the 49 examples of I gave Ki values of <10 μM, indicating that they are expected to show useful therapeutic activity. For example, II and 5-[(2,3-difluorobenzyl)sulfinyl]-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino][1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one gave Ki values of 44.6 and 38.0 nM resp. Representative solubility data are shown in which 8 examples of I have much greater solubility than the corresponding thioether analogs of other inventions.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:267340 CAPLUS
DOCUMENT NUMBER: 140:303689
TITLE: Preparation of 5-{[(2,3-difluorophenyl)methyl]thio}-7-{[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist
INVENTOR(S): Bonnert, Roger Victor
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026880	A1	20040401	WO 2003-GB3998	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498762	A1	20040401	CA 2003-2498762	20030916
AU 2003267571	A1	20040408	AU 2003-267571	20030916
AU 2003267571	B2	20070816		
EP 1543013	A1	20050622	EP 2003-748263	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014844	A	20050809	BR 2003-14844	20030916
CN 1681826	A	20051012	CN 2003-822335	20030916
JP 2006503835	T	20060202	JP 2004-537276	20030916
NZ 538826	A	20061222	NZ 2003-538826	20030916
MX 2005PA02935	A	20050527	MX 2005-PA2935	20050316
ZA 2005002272	A	20050919	ZA 2005-2272	20050317
NO 2005001892	A	20050617	NO 2005-1892	20050419
US 2006100221	A1	20060511	US 2005-528316	20051201
PRIORITY APPLN. INFO.:			GB 2002-21828 A	20020920
			WO 2003-GB3998 W	20030916

OTHER SOURCE(S): MARPAT 140:303689
IT 676345-22-5P 676345-23-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multi-step preparation of 5-{[(2,3-difluorophenyl)methyl]thio}-7-{[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)
RN 676345-22-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]- (CA INDEX NAME)



RN 676345-23-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

IT 259101-71-8P 676345-26-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(multi-step preparation of 5-{[(2,3-difluorophenyl)methyl]thio}-7-{[(2-hydroxy-1-(hydroxymethyl)-1-methylethyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)
RN 259101-71-8 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 676345-26-9 CAPLUS
CN 1,3-Propanediol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compound I and its monosodium salt, useful for treating a chemokine mediated diseases such as asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis, cancer, etc., were prepared in a multi-step process, starting from 4-amino-6-hydroxy-2-mercaptopyrimidine and 2,3-difluorobenzyl bromide. The compound I showed IC50 of < 10 μM against hrCXCR2 binding. The latter was also tested in intracellular calcium mobilisation assay and found to be an antagonist of the CXCR2 receptor in human neutrophils. A process for the preparation of the compound I which comprises reaction of II [R = alkyl] with an acid is claimed. The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:267303 CAPLUS
DOCUMENT NUMBER: 140:303685
TITLE: Preparation of 5-{[(2,3-difluorophenyl)methyl]thio}-7-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist
INVENTOR(S): Brough, Stephen John; McInally, Thomas
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026835	A1	20040401	WO 2003-GB4000	20030916
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498760	A1	20040401	CA 2003-2498760	20030916
AU 2003264765	A1	20040408	AU 2003-264765	20030916
EP 1542974	A1	20050622	EP 2003-797377	20030916
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014843	A	20050809	BR 2003-14843	20030916
CN 1681787	A	20051012	CN 2003-822336	20030916
JP 2006503836	T	20060202	JP 2004-537278	20030916
MX 2005PA02936	A	20050728	MX 2005-PA2936	20050316
ZA 2005002267	A	20050919	ZA 2005-2267	20050317
US 2005272750	A1	20051208	US 2005-528270	20050317
NO 2005001893	A	20050617	NO 2005-1893	20050419
PRIORITY APPLN. INFO.:			GB 2002-21829 A	20020920
			WO 2003-GB4000 W	20030916

OTHER SOURCE(S): MARPAT 140:303685
IT 676345-69-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(multi-step preparation of 5-{[(2,3-difluorophenyl)methyl]thio}-7-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)
RN 676345-69-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 676345-70-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(multi-step preparation of 5-{[(2,3-difluorophenyl)methyl]thio}-7-{[(1S,2S)-2-hydroxy-1-(hydroxymethyl)propyl]amino}thiazolo[4,5-d]pyrimidin-2(3H)-one as CXCR2 receptor antagonist)
RN 676345-70-3 CAPLUS
CN 1,3-Butanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S,3S)- (CA INDEX NAME)

Absolute stereochemistry.



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compound I, useful for treating a chemokine mediated diseases such as asthma, allergic rhinitis, COPD, inflammatory bowel disease, osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis, cancer, etc., was prepared in a 7-step process, starting from 4-amino-6-hydroxy-2-mercaptopyrimidine and 2,3-difluorobenzyl bromide. The compound I showed IC50 of < 10 μM against hrCXCR2 binding. The latter was also tested in

intracellular calcium mobilisation assay and found to be an antagonist of the CXCR2 receptor in human neutrophils. A process for the preparation of the compound I which comprises reaction of II [R = alkyl] with an acid is claimed. The pharmaceutical composition comprising the compound I is claimed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:814150 CAPLUS
DOCUMENT NUMBER: 137:325430
TITLE: Preparation of thiazolopyrimidines as modulators of chemokine receptor activity
INVENTOR(S): Bonnert, Roger
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083693	A1	20021024	WO 2002-SE731	20020412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002255401	A1	20021028	AU 2002-255401	20020412
EP 1385854	A1	20040204	EP 2002-724837	20020412
EP 1385854	B1	20050209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525972	T	20040826	JP 2002-581448	20020412
AT 288919	T	20050215	AT 2002-724837	20020412
US 2004157853	A1	20040812	US 2003-474610	20031009
US 6949643	B2	20050927		
US 2006111569	A1	20060525	US 2005-225379	20050912
PRIORITY APPLN. INFO.:			SE 2001-1322 A	20010412
			WO 2002-SE731 W	20020412
			US 2003-474610 A1	20031009

OTHER SOURCE(S): MARPAT 137:325430
IT 333742-48-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolopyrimidines as modulators of chemokine receptor activity)
RN 333742-48-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 333743-03-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolopyrimidines as modulators of chemokine receptor activity)
RN 333743-03-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



GI



I



II



III



IV

AB The title compds. [I; A = II, III; R1 = cycloalkyl, alkyl, alkenyl, etc.; R2, R3 = H, cycloalkyl, alkyl, etc.; X = CH, CCN; Y = N, CR18; R18 = H, alkyl, Ph], useful for treating a chemokine mediated disease such as psoriasis, rheumatoid arthritis, and COPD, were prepared E.g., a 5-step synthesis of (1R)-IV, starting from 2-amino-5,6-dihydro-5-thioxothiazolo[4,5-d]pyrimidin-7(4H)-one and 2,3-difluorobenzyl bromide, was given. The compds. I were found to have IC50 values of < 10 μM against CXCR2 receptor binding. They were also tested against chemokine GROα (no data given).

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:754394 CAPLUS
DOCUMENT NUMBER: 137:263057
TITLE: Preparation of thiazolo[4,5-d]pyrimidinyldiamines as CX3CR1 receptor antagonists
INVENTOR(S): Hanson, Sverker; Nordvall, Gunnar
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076990	A1	20021003	WO 2002-SE599	20020326
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002245005	A1	20021008	AU 2002-245005	20020326
EP 1377590	A1	20040107	EP 2002-713341	20020326
EP 1377590	B1	20070815		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004524351	T	20040812	JP 2002-576248	20020326
AT 370147	T	20070915	AT 2002-713341	20020326
US 2004106628	A1	20040603	US 2003-472992	20030925
US 7067657	B2	20060627		
PRIORITY APPLN. INFO.:			SE 2001-1082 A	20010327
			WO 2002-SE599 W	20020326

OTHER SOURCE(S): MARPAT 137:263057
IT 463953-89-1P 463953-90-4P 463953-91-5P
463953-92-6P 463953-93-7P 463953-94-8P
463953-95-9P 463953-96-0P 463953-97-1P
463953-98-2P 463953-99-3P 463954-00-9P
463954-01-0P 463954-02-1P 463954-03-2P
463954-04-3P 463954-05-4P 463954-06-5P
463954-07-6P 463954-08-7P 463954-09-8P
463954-10-1P 463954-11-2P 463954-12-3P
463954-13-4P 463954-14-5P 463954-15-6P
463954-16-7P 463954-17-8P 463954-18-9P
463954-19-0P 463954-20-3P 463954-21-4P
463954-22-5P 463954-23-6P 463954-24-7P
463954-25-8P 463954-26-9P 463954-27-0P
463954-28-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolo[4,5-d]pyrimidinyldiamines as CX3CR1 receptor antagonists)

RN 463953-89-1 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methyl- (CA INDEX NAME)



RN 463953-90-4 CAPLUS
CN 1-Hexanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 463953-91-5 CAPLUS
CN Acetamide, 2-[[7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 463953-92-6 CAPLUS
CN 1-Pentanol, 4-methyl-2-[[5-[(phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463953-93-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463953-94-8 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463953-95-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463953-96-0 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463953-97-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(4-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463953-98-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-iodophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463953-99-3 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2,4-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-00-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2,5-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-01-0 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2,6-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-02-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3,4-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-03-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3,5-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-04-3 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3-chloro-2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-05-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-chloro-6-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-06-5 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(4-bromo-2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-07-6 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-bromo-5-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-08-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2,3-dichlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-09-8 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(6-chloro-1,3-benzodioxol-5-yl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-10-1 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-11-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-12-3 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(4-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-13-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-14-5 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-15-6 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-bromo-5-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-16-7 CAPLUS
CN Benzoic acid, 3-[[[2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-17-8 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[[4-(trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-18-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[[2-(trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-19-0 CAPLUS
CN Benzonitrile, 4-[[[2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-20-3 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(4-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-21-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-22-5 CAPLUS
CN Benzonitrile, 2-[[[2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-23-6 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-24-7 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[[3-(trifluoromethyl)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-25-8 CAPLUS
CN Benzonitrile, 3-[[[2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-26-9 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3-methyl-2-nitrophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-27-0 CAPLUS
CN Cyclopentanemethanol, 1-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 463954-28-1 CAPLUS

CN 1-Hexanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



IT 259101-09-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of thiazolo[4,5-d]pyrimidinyldiamines as CX3CR1 receptor antagonists)

RN 259101-09-2 CAPLUS

CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 463954-31-6P 463954-32-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolo[4,5-d]pyrimidinyldiamines as CX3CR1 receptor antagonists)

RN 463954-31-6 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 463954-32-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



GI



AB The title compds. [I; R1 = H, NR4R5, CONR6R7, 4-7 membered saturated monoazacyclic ring optionally substituted by alkyl or alkyl-OR8; R2 = alkyl, optionally substituted by OR9, NR10R11; R3 = H, alkyl, optionally substituted by OR12, NR13R14; or CR2R3 = cycloalkyl, optionally substituted by OR9 or NR10R11; Ar = (un)substituted Ph; X = a bond, alkyl; R4-R14 = H, alkyl], useful for the treatment or prophylaxis of diseases or conditions in which antagonism of the CX3CR1 receptor is beneficial,

particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease and pain, were prepared Thus, reacting 5-phenylmethylthio-7-chlorothiazolo[4,5-d]pyrimidin-2-ylamine with DL-2-amino-3-methyl-1-butanol in THF afforded 24% (±)-I [R1 = H; R2 = iso-Pr; R3 = H; Ar = Ph; X = a bond]. The exemplified compds. I showed Ki of < 10 μM in the SPA-ligand binding assay.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:597993 CAPLUS
DOCUMENT NUMBER: 135:166841
TITLE: Preparation of thiazolopyrimidines as modulators of chemokine receptor activity
INVENTOR(S): Bonnert, Roger; Cage, Peter; Hunt, Fraser; Jewell, Robert; Walters, Iain
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001058907	A1	20010816	WO 2001-SE247	20010207
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2359081	A	20010815	GB 2000-3025	20000211
EP 1257556	A1	20021120	EP 2001-906447	20010207
EP 1257556	B1	20040616		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003522192	T	20030722	JP 2001-558056	20010207
AT 269340	T	20040715	AT 2001-906447	20010207
US 2003032642	A1	20030213	US 2002-203580	20020809
US 6958343	B2	20051025		

PRIORITY APPLN. INFO.: GB 2000-3025 A 20000211
WO 2001-SE247 W 20010207

OTHER SOURCE(S): MARPAT 135:166841
IT 333743-41-2P 333743-44-5P 333743-47-8P
333744-06-2P 354565-81-4P 354565-82-5P
354565-83-6P 354565-84-7P 354565-85-8P
354565-86-9P 354565-87-0P 354565-88-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazolopyrimidines as modulators of chemokine receptor activity)
RN 333743-41-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-44-5 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333743-47-8 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 333744-06-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-81-4 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(1H-benzimidazol-2-ylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 354565-82-5 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 354565-83-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[1-(2-thienyl)ethyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 354565-84-7 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3,5-dimethyl-4-isoxazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-85-8 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(5-methyl-2-furanyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-86-9 CAPLUS
CN Acetamide, N-[4-[[[2-amino-7-[[(1R)-2-hydroxy-1-methylethyl]amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]methyl]-2-thiazolyl]-

(CA INDEX NAME)

Absolute stereochemistry.



RN 354565-87-0 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(5-isoxazolylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-88-1 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(2-furanylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 259101-61-6P 333742-99-7P 333743-71-8P
354565-89-2P 354565-90-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazolopyrimidines as modulators of chemokine receptor activity)

RN 259101-61-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 333742-99-7 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-71-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 354565-89-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 354565-90-5 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



GI



I

AB The title compds. [I; R = H, NR4R5 (R4, R5 = H, 4-piperidinyl, cycloalkyl, etc.; NR4R5 = (un)substituted 4-7 membered saturated heterocyclyl); R1 = alkyl optionally containing one or more atoms selected from O, S, NR6 (R6 = H, alkyl, Ph) which terminates in (un)substituted heteroaryl group; R3, R3 = H, alkyl, cycloalkyl, etc.; NR2R3 = (un)substituted 3-8 membered ring optionally containing one or more atoms selected from O, S, NR9 (NR9 = H, alkyl, Ph)], useful in treating an inflammatory diseases such as psoriasis and COPD, were prepared E.g., a multi-step synthesis of I [R = NH2; R1 = 1H-benzimidazol-2-ylmethyl; R2 = CMe2CH2OH; R3 = H] was given. The compds. I were found to have IC50 of < 10 μM against CXCR2 receptor binding.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:265425 CAPLUS
DOCUMENT NUMBER: 134:280857
TITLE: Preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors
INVENTOR(S): Willis, Paul Andrew; Bonnert, Roger Victor; Hunt, Simon Fraser; Walters, Iain Alistair Stewart
PATENT ASSIGNEE(S): Astrazeneca UK Limited, UK
SOURCE: PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001025242	A1	20010412	WO 2000-GB3692	20000926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2385269	A1	20010412	CA 2000-2385269	20000926
BR 2000014334	A	20020611	BR 2000-14334	20000926
EP 1222195	A1	20020717	EP 2000-960891	20000926
EP 1222195	B1	20040114		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511384	T	20030325	JP 2001-528186	20000926
EE 200200174	A	20030415	EE 2002-174	20000926
HU 2002004246	A2	20030428	HU 2002-4246	20000926
HU 2002004246	A3	20060130		
NZ 517880	A	20030926	NZ 2000-517880	20000926
EP 1348709	A2	20031001	EP 2003-15019	20000926
EP 1348709	A3	20031119		
EP 1348709	B1	20080116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 257838	T	20040115	AT 2000-960891	20000926
PT 1222195	T	20040531	PT 2000-960891	20000926
ES 2213043	T3	20040816	ES 2000-960891	20000926
AU 777872	B2	20041104	AU 2000-73049	20000926
TW 260324	B	20060821	TW 2000-89121952	20001019
IN 2002MN00313	A	20050318	IN 2002-MN313	20020314
NO 2002001448	A	20020522	NO 2002-1448	20020322
ZA 2002002380	A	20030804	ZA 2002-2380	20020325
MX 2002PA03263	A	20020930	MX 2002-PA3263	20020327
US 6790850	B1	20040914	US 2002-89571	20020329
KR 765051	B1	20071009	KR 2002-704180	20020330
HK 1052009	A1	20060113	HK 2003-104330	20030617
US 2004224961	A1	20041111	US 2004-863995	20040609
IN 2007MN01406	A	20071102	IN 2007-MN1406	20070912

PRIORITY APPLN. INFO.:

SE 1999-3544	A	19991001
EP 2000-960891	A3	20000926
WO 2000-GB3692	W	20000926
IN 2002-MN313	A3	20020314
US 2002-89571	A1	20020329

OTHER SOURCE(S): MARPAT 134:280857

IT 333742-46-4P 333742-48-6P 333742-63-5P
333742-86-2P 333742-87-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)

RN 333742-46-4 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-48-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-63-5 CAPLUS

CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(3-chloro-2-fluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-86-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(methoxymethyl)ethyl]amino]- (CA INDEX NAME)



RN 333742-87-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)



IT 333742-56-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)

RN 333742-56-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-amino-1-methylethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 333742-55-5
CMF C15 H15 F2 N5 O S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



IT 333742-44-2P 333742-45-3P 333742-47-5P
333742-49-7P 333742-50-0P 333742-51-1P
333742-52-2P 333742-53-3P 333742-54-4P
333742-55-5P 333742-57-7P 333742-58-8P
333742-59-9P 333742-60-2P 333742-61-3P
333742-62-4P 333742-64-6P 333742-65-7P
333742-66-8P 333742-67-9P 333742-68-0P
333742-69-1P 333742-70-4P 333742-71-5P
333742-72-6P 333742-73-7P 333742-74-8P
333742-75-9P 333742-76-0P 333742-77-1P
333742-78-2P 333742-79-3P 333742-80-6P
333742-81-7P 333742-82-8P 333742-83-9P
333742-84-0P 333742-85-1P 333742-88-4P
333742-89-5P 333742-90-8P 333742-91-9P
333742-92-0P 333742-93-1P 333742-94-2P
333742-95-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)

RN 333742-44-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)



RN 333742-45-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-1-(hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-47-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]- (CA INDEX NAME)



RN 333742-49-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-(2-hydroxyethoxy)ethyl]amino]- (CA INDEX NAME)



RN 333742-50-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]- (CA INDEX NAME)



RN 333742-51-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-aminoethyl)amino]-5-[[(2,3-difluorophenyl)methyl]thio]- (CA INDEX NAME)



RN 333742-52-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxyethyl)amino]- (CA INDEX NAME)



RN 333742-53-3 CAPLUS
CN Methanesulfonamide, N-[2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2,3-dihydro-2-oxothiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]- (CA INDEX NAME)



RN 333742-54-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-(2-hydroxyethoxy)-1-methylethyl]amino]- (CA INDEX NAME)



RN 333742-55-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-amino-1-methylethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-57-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-[(2-hydroxyethyl)amino]-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-58-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-[(2-hydroxyethyl)amino]-1-methylethyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 333742-57-7
CMF C17 H19 F2 N5 O2 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 333742-59-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-(dimethylamino)-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-60-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[2-(2-aminoethoxy)-3-chlorophenyl]methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-61-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[2-(2-aminoethoxy)-3-chlorophenyl]methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 333742-60-2
CMF C17 H20 Cl N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 333742-62-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(3-chloro-4-methoxyphenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-64-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(3R,4R)-4-hydroxy-3-pyrrolidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-65-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[(3R)-3-pyrrolidinylamino]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 333742-66-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[[(2-methyl-4-thiazolyl)methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-67-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-[[(2-methyl-4-thiazolyl)methyl]thio]- (CA INDEX NAME)



RN 333742-68-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[[(2-methyl-4-thiazolyl)methyl]thio]- (CA INDEX NAME)



RN 333742-69-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[[(2-methylphenyl)methyl]thio]- (CA INDEX NAME)



RN 333742-70-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[(2-furanylmethyl)thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-71-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-amino-1-methylethyl]amino]-5-[[(3-chloro-2-fluorophenyl)methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-72-6 CAPLUS
CN Propanamide, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2,3-dihydro-2-oxothiazolo[4,5-d]pyrimidin-7-yl]amino]-3-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-73-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(2-thienylmethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-74-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[[[3-methyl-4-(methylsulfonyl)phenyl]methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-75-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[3-chloro-4-(trifluoromethoxy)phenyl]methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-76-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-77-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-(dimethylamino)ethyl]amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 333742-78-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2-fluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-79-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[[(2-methoxyphenyl)methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-80-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(2-phenoxyethyl)thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-81-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[[(3-methylphenyl)methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-82-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2-fluoro-3-methylphenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-83-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(3-chlorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-84-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(3-bromophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-85-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[[4-(difluoromethoxy)phenyl]methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-88-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2-bromophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-89-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 333742-90-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(3-chloro-2-fluorophenyl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 333742-91-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[[2-hydroxy-1-(methoxymethyl)ethyl]amino]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 333742-92-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-5-[(phenylmethyl)thio]-, monosodium salt (9CI) (CA INDEX NAME)



● Na

RN 333742-93-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(phenylmethyl)thio]-, monosodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-94-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-95-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 5-[[(2,3-difluorophenyl)methyl]thio]-7-[(3R)-3-pyrrolidinylamino]- (CA INDEX NAME)

Absolute stereochemistry.



IT 259100-39-5P 259101-56-9P 259101-61-6P
259101-68-3P 259101-74-1P 259101-81-0P
333742-96-4P 333742-98-6P 333742-99-7P
333743-01-4P 333743-02-5P 333743-03-6P
333743-05-8P 333743-07-0P 333743-09-2P
333743-10-5P 333743-12-7P 333743-14-9P
333743-15-0P 333743-17-2P 333743-18-3P
333743-20-7P 333743-21-8P 333743-22-9P
333743-23-0P 333743-25-2P 333743-30-9P
333743-32-1P 333743-34-3P 333743-35-4P
333743-37-6P 333743-41-2P 333743-43-4P
333743-44-5P 333743-46-7P 333743-47-8P
333743-49-0P 333743-50-3P 333743-55-8P
333743-56-9P 333743-57-0P 333743-59-2P
333743-60-5P 333743-71-8P 333743-72-9P
333743-74-1P 333743-75-2P 333743-77-4P
333743-78-5P 333743-80-9P 333743-81-0P
333743-83-2P 333743-84-3P 333743-86-5P
333743-87-6P 333743-89-8P 333743-90-1P
333743-92-3P 333743-93-4P 333743-95-6P
333743-97-8P 333743-99-0P 333744-00-6P
333744-02-8P 333744-03-9P 333744-05-1P
333744-06-2P 333744-08-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel thiazolo[4,5-d]pyrimidines as modulators of chemokine receptors)

RN 259100-39-5 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-56-9 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-61-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-68-3 CAPLUS
CN Ethanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-74-1 CAPLUS
CN Ethanol, 2-[2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]- (CA INDEX NAME)



RN 259101-81-0 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333742-96-4 CAPLUS
CN 1-Propanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 333742-98-6 CAPLUS
CN 1-Butanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333742-99-7 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-01-4 CAPLUS
CN 1-Propanol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-02-5 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 333743-03-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-05-8 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-07-0 CAPLUS
CN Ethanol, 2-[2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-

d]pyrimidin-7-yl]amino]ethoxy]- (CA INDEX NAME)



RN 333743-09-2 CAPLUS
CN 1,3-Propanediol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333743-10-5 CAPLUS
CN Carbamic acid, [2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 333743-12-7 CAPLUS
CN Carbamic acid, [2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 333743-14-9 CAPLUS
CN Ethanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333743-15-0 CAPLUS
CN Methanesulfonamide, N-[2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]- (CA INDEX NAME)



RN 333743-17-2 CAPLUS
CN Methanesulfonamide, N-[2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]- (CA INDEX NAME)



RN 333743-18-3 CAPLUS
CN Ethanol, 2-[2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propoxy]- (CA INDEX NAME)



RN 333743-20-7 CAPLUS
CN Ethanol, 2-[2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]propoxy]- (CA INDEX NAME)



RN 333743-21-8 CAPLUS
CN Propanamide, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-22-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[(1R)-2-amino-1-methylethyl]-5-[[(2,3-difluorophenyl)methyl]thio]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-23-0 CAPLUS
CN Carbamic acid, [(2R)-2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-25-2 CAPLUS
CN Carbamic acid, [(2R)-2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-30-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-[(phenylmethyl)sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-32-1 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-hydroxy-, 1,1-dimethylethyl ester, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-34-3 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-4-hydroxy-, 1,1-dimethylethyl ester, (3R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-35-4 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-37-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, 1,1-dimethylethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-41-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-43-4 CAPLUS

CN 1-Propanol, 2-[[2-methoxy-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-44-5 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333743-46-7 CAPLUS
CN 1,3-Propanediol, 2-[[2-methoxy-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333743-47-8 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 333743-49-0 CAPLUS
CN 1-Propanol, 2-[[2-methoxy-5-[[(2-methyl-4-thiazolyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 333743-50-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidin-2(3H)-one, 7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)sulfonyl]- (CA INDEX NAME)



RN 333743-55-8 CAPLUS
CN Carbamic acid, [(2R)-2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-56-9 CAPLUS
CN Carbamic acid, [(2R)-2-[[2-amino-5-[(phenylmethyl)sulfonyl]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-57-0 CAPLUS
CN Carbamic acid, [(2R)-2-[[2-amino-5-[[(3-chloro-2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-59-2 CAPLUS

CN Carbamic acid, [(2R)-2-[[5-[[(3-chloro-2-fluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-60-5 CAPLUS
CN Propanamide, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-hydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-71-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-5(4H)-thione, 2-amino-7-[[(1R)-2-hydroxy-1-methylethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-72-9 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-fluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-74-1 CAPLUS
CN 1-Propanol, 2-[[5-[[(2-fluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-75-2 CAPLUS

CN 1-Propanol, 2-[[2-amino-5-[[(2-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-77-4 CAPLUS
CN 1-Propanol, 2-[[2-methoxy-5-[[(2-methoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-78-5 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-80-9 CAPLUS
CN 1-Propanol, 2-[[2-methoxy-5-[(2-phenoxyethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-81-0 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-83-2 CAPLUS
CN 1-Propanol, 2-[[2-methoxy-5-[[(3-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-84-3 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-fluoro-3-methylphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-86-5 CAPLUS
CN 1-Propanol, 2-[[5-[[(2-fluoro-3-methylphenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-87-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-chlorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-89-8 CAPLUS
CN 1-Propanol, 2-[[5-[[(3-chlorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-90-1 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-92-3 CAPLUS
CN 1-Propanol, 2-[[5-[[(3-bromophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-93-4 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[[4-(difluoromethoxy)phenyl]methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-95-6 CAPLUS
CN 1-Propanol, 2-[[5-[[[4-(difluoromethoxy)phenyl]methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333743-97-8 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methoxy- (CA INDEX NAME)



RN 333743-99-0 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-3-methoxy- (CA INDEX NAME)



RN 333744-00-6 CAPLUS

CN 1,3-Propanediol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333744-02-8 CAPLUS
CN 1,3-Propanediol, 2-[[2-methoxy-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 333744-03-9 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2-bromophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333744-05-1 CAPLUS
CN 1-Propanol, 2-[[5-[[(2-bromophenyl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333744-06-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 333744-08-4 CAPLUS
CN 1-Propanol, 2-[[5-[[(5-chloro-1,2,3-thiadiazol-4-yl)methyl]thio]-2-methoxythiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



GI



I

AB The title compds. [I; R1 = alkyl, alkenyl, cycloalkyl, etc.; R2, R3 = H, alkyl, cycloalkyl, etc.], useful in treating a chemokine mediated disease, were prepared E.g., a multi-step synthesis of I [R1 = CH2Ph; R2 = CMe2CH2OH; R3 = H] was described. The compds. I were tested and found to be antagonists of the CXCR2 receptor in human neutrophils.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:133684 CAPLUS
DOCUMENT NUMBER: 132:166252
TITLE: Preparation of novel thiazolopyrimidines as modulators of chemokine receptor activity
INVENTOR(S): Austin, Rupert; Baxter, Andrew; Bonnert, Roger; Hunt, Fraser; Kinchin, Elizabeth; Willis, Paul
PATENT ASSIGNEE(S): Astra Pharmaceuticals Ltd., UK; Astra AB
SOURCE: PCT Int. Appl., 155 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000009511	A1	20000224	WO 1999-SE1333		19990803
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2338600	A1	20000224	CA 1999-2338600		19990803
CA 2338600	C	20080108			
AU 9956625	A	20000306	AU 1999-56625		19990803
AU 768004	B2	20031127			
EP 1104425	A1	20010606	EP 1999-943554		19990803
EP 1104425	B1	20030129			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002522544	T	20020723	JP 2000-564962		19990803
AT 231872	T	20030215	AT 1999-943554		19990803
ES 2190246	T3	20030716	ES 1999-943554		19990803
US 6806273	B1	20041019	US 2001-403392		20011021
PRIORITY APPLN. INFO.:			SE 1998-2729	A	19980813
			WO 1999-SE1333	W	19990803

OTHER SOURCE(S): MARPAT 132:166252
IT 259101-56-9P 259101-61-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of novel thiazolopyrimidines as modulators of chemokine receptor activity)
RN 259101-56-9 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-61-6 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



IT 259100-39-5P 259100-40-8P 259100-44-2P
259100-45-3P 259100-66-8P 259100-67-9P
259100-68-0P 259100-69-1P 259100-70-4P
259100-71-5P 259100-72-6P 259100-73-7P
259100-74-8P 259100-75-9P 259100-76-0P
259100-77-1P 259100-78-2P 259100-79-3P
259100-80-6P 259100-81-7P 259100-82-8P
259101-05-8P 259101-06-9P 259101-07-0P
259101-08-1P 259101-09-2P 259101-10-5P
259101-11-6P 259101-12-7P 259101-13-8P
259101-18-3P 259101-19-4P 259101-20-7P
259101-21-8P 259101-22-9P 259101-23-0P
259101-24-1P 259101-25-2P 259101-26-3P
259101-27-4P 259101-28-5P 259101-29-6P
259101-30-9P 259101-31-0P 259101-32-1P
259101-33-2P 259101-34-3P 259101-35-4P
259101-36-5P 259101-37-6P 259101-38-7P
259101-39-8P 259101-40-1P 259101-41-2P
259101-42-3P 259101-43-4P 259101-44-5P
259101-51-4P 259101-52-5P 259101-53-6P
259101-54-7P 259101-55-8P 259101-57-0P
259101-58-1P 259101-59-2P 259101-60-5P
259101-62-7P 259101-63-8P 259101-65-0P
259101-66-1P 259101-67-2P 259101-68-3P
259101-69-4P 259101-70-7P 259101-71-8P
259101-72-9P 259101-73-0P 259101-74-1P
259101-75-2P 259101-77-4P 259101-78-5P
259101-80-9P 259101-81-0P 259101-82-1P

259101-83-2P 259101-84-3P 259101-85-4P
259101-86-5P 259101-87-6P 259101-88-7P
259101-89-8P 259101-90-1P 259101-91-2P
259101-92-3P 259101-93-4P 259101-94-5P
259101-95-6P 259101-96-7P 259101-97-8P
259101-98-9P 259101-99-0P 259102-00-6P
259102-01-7P 259102-10-8P 259102-11-9P
259102-12-0P 259102-13-1P 259102-14-2P
259102-15-3P 259102-16-4P 259102-17-5P
259102-18-6P 259102-19-7P 259102-20-0P
259102-21-1P 259102-22-2P 259102-23-3P
259102-24-4P 259102-25-5P 259102-26-6P
259102-27-7P 259102-28-8P 259102-29-9P
259102-30-2P 259102-31-3P 259102-32-4P
259102-33-5P 259102-34-6P 259102-35-7P
259102-36-8P 259102-37-9P 259102-38-0P
259102-39-1P 259102-40-4P 259102-41-5P
259102-42-6P 259102-43-7P 259102-44-8P
259102-45-9P 259102-46-0P 259102-47-1P
259102-48-2P 259102-49-3P 259102-50-6P
259102-51-7P 259102-52-8P 259102-53-9P
259102-54-0P 259102-57-3P 259102-58-4P
259102-59-5P 259102-61-9P 259102-62-0P
259102-63-1P 259102-64-2P 259102-66-4P
259102-68-6P 259102-69-7P 259102-70-0P
259102-71-1P 259102-73-3P 259102-74-4P
259102-75-5P 259102-76-6P 259102-77-7P
259102-78-8P 259102-79-9P 259102-82-4P
259102-83-5P 259102-84-6P 259102-86-8P
259102-87-9P 259102-88-0P 259102-89-1P
259102-90-4P 259102-93-7P 259102-94-8P
259102-95-9P 259102-96-0P 259102-98-2P
259102-99-3P 259103-00-9P 259103-01-0P
259103-02-1P 259103-03-2P 259103-04-3P
259103-05-4P 259103-06-5P 259103-08-7P
259103-09-8P 259103-10-1P 259103-11-2P
259103-13-4P 259103-14-5P 259103-15-6P
259103-16-7P 259103-17-8P 259103-18-9P
259103-19-0P 259103-21-4P 259103-24-7P
259103-25-8P 259103-26-9P 259103-28-1P
259103-32-7P 259103-33-8P 259103-34-9P
259103-35-0P 259104-23-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel thiazolopyrimidines as modulators of chemokine receptor activity)

RN 259100-39-5 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259100-40-8 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259100-44-2 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259100-45-3 CAPLUS
CN Ethanol, 2-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259100-66-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[3-(dimethylamino)propyl]-5-(pentylthio)- (CA INDEX NAME)



RN 259100-67-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[2-(diethylamino)ethyl]-5-(pentylthio)- (CA INDEX NAME)



RN 259100-68-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[2-(dimethylamino)ethyl]-5-(pentylthio)- (CA INDEX NAME)



RN 259100-69-1 CAPLUS
CN 1-Propanol, 3-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259100-70-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclohexyl-5-(pentylthio)- (CA INDEX NAME)



RN 259100-71-5 CAPLUS
CN 1,2-Propanediol, 3-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259100-72-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-methoxyethyl)-5-(pentylthio)- (CA INDEX NAME)



RN 259100-73-7 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-(pentylthio)-N7-propyl- (CA

INDEX NAME)



RN 259100-74-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclopentyl-5-(pentylthio)- (CA INDEX NAME)



RN 259100-75-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclopropyl-5-(pentylthio)- (CA INDEX NAME)



RN 259100-76-0 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-methylpropyl)-5-(pentylthio)- (CA INDEX NAME)



RN 259100-77-1 CAPLUS
CN 2-Propanol, 1-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259100-78-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(1R,2S,4S)-bicyclo[2.2.1]hept-2-yl-5-(pentylthio)-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 259100-79-3 CAPLUS
CN Ethanol, 2-[2-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]- (CA INDEX NAME)



RN 259100-80-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-methylbutyl)-5-(pentylthio)- (CA INDEX NAME)



RN 259100-81-7 CAPLUS
CN 2-Propanol, 1-[[2-amino-5-(pentylthio)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259100-82-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[(2-aminophenyl)methyl]-5-(pentylthio)- (CA INDEX NAME)



RN 259101-05-8 CAPLUS
CN 1-Propanol, 3-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2,2-dimethyl- (CA INDEX NAME)



RN 259101-06-9 CAPLUS
CN Benzenemethanol, α-[[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]- (CA INDEX NAME)



RN 259101-07-0 CAPLUS
CN Benzenepropanol, β-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-08-1 CAPLUS
CN Ethanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-09-2 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-10-5 CAPLUS
CN 2-Propanol, 1-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-11-6 CAPLUS
CN Benzenepropanol, β-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chloro- (CA INDEX NAME)



RN 259101-12-7 CAPLUS
CN 1,2-Propanediol, 3-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-13-8 CAPLUS
CN Ethanol, 2-[[2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)



RN 259101-18-3 CAPLUS
CN 1-Propanol, 3-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2,2-dimethyl- (CA INDEX NAME)



RN 259101-19-4 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-20-7 CAPLUS
CN Benzenemethanol, α-[[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]- (CA INDEX NAME)



RN 259101-21-8 CAPLUS
CN 1-Butanol, 4-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-22-9 CAPLUS
CN 1-Hexanol, 6-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-23-0 CAPLUS
CN Cyclohexanol, 4-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-24-1 CAPLUS
CN Benzenepropanol, β-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-25-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-26-3 CAPLUS
CN Ethanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-27-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-28-5 CAPLUS
CN 2-Propanol, 1-amino-3-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-29-6 CAPLUS
CN 2-Propanol, 1-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-30-9 CAPLUS
CN 1,3-Propanediol, 2-[[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-2-ethyl- (CA INDEX NAME)



RN 259101-31-0 CAPLUS
CN Benzenepropanol, β-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-chloro- (CA INDEX NAME)



RN 259101-32-1 CAPLUS
CN 1,2-Propanediol, 3-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-33-2 CAPLUS
CN Ethanol, 2-[[2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]amino]- (CA INDEX NAME)



RN 259101-34-3 CAPLUS
CN 1-Propanol, 3-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-35-4 CAPLUS
CN Benzenepropanol, γ-[[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]-3,4-dichloro- (CA INDEX NAME)



RN 259101-36-5 CAPLUS
CN 2-Propanol, 1-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-37-6 CAPLUS
CN Ethanol, 2-[2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]- (CA INDEX NAME)



RN 259101-38-7 CAPLUS
CN 1-Pentanol, 5-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-39-8 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-(methylthio)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-40-1 CAPLUS
CN Ethanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]butylamino]- (CA INDEX NAME)



RN 259101-41-2 CAPLUS
CN Ethanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]propylamino]- (CA INDEX NAME)



RN 259101-42-3 CAPLUS
CN Ethanol, 2,2'-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]imino]bis- (9CI) (CA INDEX NAME)



RN 259101-43-4 CAPLUS
CN Phenol, 2-[[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl](2-hydroxyethyl)amino]methyl]- (CA INDEX NAME)



RN 259101-44-5 CAPLUS
CN 1-Propanol, 3-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl](2-hydroxyethyl)amino]- (CA INDEX NAME)



RN 259101-51-4 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-52-5 CAPLUS

CN 1-Butanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-53-6 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-54-7 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-55-8 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(3-phenoxyphenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-57-0 CAPLUS
CN 2-Propanol, 1-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-58-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[(2,3-difluorophenyl)methyl]thio]-N7-(2-fluoroethyl)- (CA INDEX NAME)



RN 259101-59-2 CAPLUS
CN Cyclopentanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-60-5 CAPLUS
CN Cyclopentanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-62-7 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-63-8 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-

[(phenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-65-0 CAPLUS
CN 1-Butanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-66-1 CAPLUS
CN Cyclohexanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-67-2 CAPLUS
CN 1-Propanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-68-3 CAPLUS
CN Ethanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-69-4 CAPLUS
CN 1-Pentanol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-70-7 CAPLUS
CN 2-Propanol, 1-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-71-8 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-72-9 CAPLUS
CN Cyclohexanol, 1-[[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]methyl]- (CA INDEX NAME)



RN 259101-73-0 CAPLUS
CN Ethanol, 2-[[2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethyl]amino]- (CA INDEX NAME)



RN 259101-74-1 CAPLUS
CN Ethanol, 2-[2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]ethoxy]- (CA INDEX NAME)



RN 259101-75-2 CAPLUS
CN Benzenemethanol, α-[(1R)-1-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]methylamino]ethyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-77-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[(2,3-difluorophenyl)methyl]thio]-N7-ethyl- (CA INDEX NAME)



RN 259101-78-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[(2,3-difluorophenyl)methyl]thio]-N7-2-propenyl- (9CI) (CA INDEX NAME)



RN 259101-80-9 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-1-phenyl-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-81-0 CAPLUS
CN 1,3-Propanediol, 2-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259101-82-1 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[(2,3-difluorophenyl)methyl]thio]-N7-(2-methoxy-1-methylethyl)- (CA INDEX NAME)



RN 259101-83-2 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-cyclopropyl-5-[[(2,3-difluorophenyl)methyl]thio]- (CA INDEX NAME)



RN 259101-84-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-[[(2,3-difluorophenyl)methyl]thio]-N7-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 259101-85-4 CAPLUS
CN L-Serine, N-[5-[[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 259101-86-5 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(1-methylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-87-6 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-(ethylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-88-7 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[[2-(1H-indol-3-yl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-89-8 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(1-naphthalenylmethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-90-1 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(2,2-diphenylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-91-2 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(2,2,2-trifluoroethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-92-3 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[[(3,4,5-

trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-93-4 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-94-5 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-95-6 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(4-methylcyclohexyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-96-7 CAPLUS
CN Acetamide, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259101-97-8 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(4-aminophenyl)ethyl]amino]-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-98-9 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[(2-fluoroethyl)amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259101-99-0 CAPLUS
CN 1-Propanol, 2-[[2-(cyclopropylamino)-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-00-6 CAPLUS
CN 1-Pentanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-7-[(2-hydroxy-1,1-dimethylethyl)amino]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259102-01-7 CAPLUS
CN 1-Propanol, 2-[[5-[[(2,3-difluorophenyl)methyl]thio]-2-[[2-(2-hydroxyethoxy)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-10-8 CAPLUS
CN 1-Propanol, 2-[[2-(cyclohexylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-11-9 CAPLUS
CN 1-Propanol, 2-[[2-[(1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-12-0 CAPLUS
CN Alanine, N-[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-, methyl ester (CA INDEX NAME)



RN 259102-13-1 CAPLUS
CN Cyclohexanol, 4-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259102-14-2 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[(4-phenylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-15-3 CAPLUS
CN 1-Propanol, 2-methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-16-4 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-17-5 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(4-aminophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-18-6 CAPLUS
CN L-Valine, N-[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-19-7 CAPLUS
CN Pentanamide, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-4-methyl-, (2S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 259102-20-0 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[(2-phenylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-21-1 CAPLUS
CN 1-Propanol, 2-[[2-[[(4-aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-22-2 CAPLUS
CN 1-Propanol, 2-methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-23-3 CAPLUS
CN 1-Propanol, 2-[[2-[(2-fluoroethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-24-4 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[[(3-nitrophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-25-5 CAPLUS
CN Benzenemethanol, α-[(1S)-1-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-26-6 CAPLUS
CN 1-Propanol, 2-methyl-2-[[5-[(phenylmethyl)thio]-2-[[(3,4,5-trimethoxyphenyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-27-7 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-28-8 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(1H-indol-3-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-29-9 CAPLUS
CN 1-Propanol, 2-[[2-[(1,1-dimethylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-30-2 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[(1-methylbutyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-31-3 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[(1-methylhexyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-32-4 CAPLUS
CN 1-Propanol, 2-[[2-[[(2-aminophenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-33-5 CAPLUS
CN 1,3-Propanediol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259102-34-6 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(ethylthio)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-35-7 CAPLUS
CN 1-Butanol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-3,3-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-36-8 CAPLUS
CN Benzenemethanol, α-[(1R)-1-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-2-methoxyethyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-37-9 CAPLUS
CN 1-Propanol, 2-[[2-(ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-38-0 CAPLUS
CN 1-Propanol, 2-[[2-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-39-1 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[(1-methylpropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-40-4 CAPLUS
CN 1-Propanol, 2-[[2-[[(4-methoxyphenyl)methyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-41-5 CAPLUS
CN 1-Propanol, 2-[[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-42-6 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (9CI) (CA INDEX NAME)



RN 259102-43-7 CAPLUS
CN 1-Propanol, 2-[[2-[(diphenylmethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-44-8 CAPLUS
CN 1-Butanol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-45-9 CAPLUS
CN 1-Propanol, 2-[[2-[(2,2-diethoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-46-0 CAPLUS
CN 1-Butanol, 4-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259102-47-1 CAPLUS
CN Cyclohexanol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-, (1S,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-48-2 CAPLUS
CN 1-Propanol, 2-[[2-[(2-hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-49-3 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-50-6 CAPLUS
CN 1-Pentanol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259102-51-7 CAPLUS
CN Acetamide, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259102-52-8 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(4-fluorophenyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-2-methyl- (CA INDEX NAME)



RN 259102-53-9 CAPLUS
CN Cyclohexanol, 2-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-54-0 CAPLUS
CN Benzenemethanol, α-[(1R)-1-[[7-[(2-hydroxy-1,1-dimethylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-57-3 CAPLUS
CN 1-Propanol, 2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-58-4 CAPLUS
CN 1-Pentanol, 4-methyl-2-[[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-59-5 CAPLUS
CN L-Serine, N-[2-(methylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-61-9 CAPLUS
CN 1-Butanol, 2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-62-0 CAPLUS
CN 1-Propanol, 2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-63-1 CAPLUS
CN 1-Pentanol, 4-methyl-2-[[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-64-2 CAPLUS
CN L-Serine, N-[5-[(phenylmethyl)thio]-2-[[(tetrahydro-2-furanyl)methyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-66-4 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-68-6 CAPLUS
CN Benzenesulfonamide, 4-[2-[[7-[[1-(hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (CA INDEX NAME)



RN 259102-69-7 CAPLUS
CN Benzenesulfonamide, 4-[2-[[7-[(2-hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (CA INDEX NAME)



RN 259102-70-0 CAPLUS
CN Benzenesulfonamide, 4-[2-[[7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-71-1 CAPLUS
CN Benzenesulfonamide, 4-[2-[[7-[(2-hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (CA INDEX NAME)



RN 259102-73-3 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-ethyl-N2-[2-(1H-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 259102-74-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-[2-(1H-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]-N7-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 259102-75-5 CAPLUS
CN 1-Butanol, 2-[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-76-6 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-77-7 CAPLUS
CN 1-Pentanol, 2-[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-78-8 CAPLUS
CN 2-Propanol, 1-[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-79-9 CAPLUS
CN 1-Pentanol, 2-[[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-82-4 CAPLUS
CN Ethanol, 2-[ethyl[2-[[2-(1H-imidazol-4-yl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 259102-83-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-[2-(1H-imidazol-4-yl)ethyl]-N7,N7-dimethyl-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 259102-84-6 CAPLUS

CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-[2-(diethylamino)ethyl]-N7-ethyl-N2-[2-(1H-imidazol-4-yl)ethyl]-5-[(phenylmethyl)thio]- (9CI) (CA INDEX NAME)



RN 259102-86-8 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-(2-phenoxyethyl)-5-[(phenylmethyl)thio]-N7-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 259102-87-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N2-(2-phenoxyethyl)-N7-[1-(phenylmethyl)-4-piperidinyl]-5-[(phenylmethyl)thio]- (CA INDEX NAME)



RN 259102-88-0 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[(2-phenoxyethyl)amino]-5-

[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-89-1 CAPLUS
CN 1-Propanol, 2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-90-4 CAPLUS
CN 1-Pentanol, 4-methyl-2-[[2-[(2-phenoxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-93-7 CAPLUS
CN 1-Butanol, 2-[[2-(cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-94-8 CAPLUS
CN 1-Propanol, 2-[[2-(cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259102-95-9 CAPLUS
CN 1-Pentanol, 2-[[2-(cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-96-0 CAPLUS
CN L-Serine, N-[2-(cyclopropylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 259102-98-2 CAPLUS
CN 1-Pentanol, 2-[[2-[[1-(hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)-(CA INDEX NAME)

Absolute stereochemistry.



RN 259102-99-3 CAPLUS
CN L-Serine, N-[2-[[1-(hydroxymethyl)butyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 259103-00-9 CAPLUS
CN 1-Pentanol, 2-[[7-[cyclohexyl(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259103-01-0 CAPLUS
CN Ethanol, 2-[2-[[7-(ethylamino)-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethoxy]- (CA INDEX NAME)



RN 259103-02-1 CAPLUS
CN Ethanol, 2-[2-[[7-[(1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethoxy]- (CA INDEX NAME)



RN 259103-03-2 CAPLUS
CN 1-Butanol, 2-[[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-04-3 CAPLUS

CN 1-Pentanol, 2-[[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259103-05-4 CAPLUS
CN Ethanol, 2-[cyclohexyl[2-[[2-(2-hydroxyethoxy)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-06-5 CAPLUS
CN 1-Propanol, 2-[[5-[(phenylmethyl)thio]-2-(4-piperidinylamino)thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-08-7 CAPLUS
CN Acetamide, N-[2-[[7-[[1-(hydroxymethyl)propyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (CA INDEX NAME)



RN 259103-09-8 CAPLUS
CN Acetamide, N-[2-[[7-[(2-hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (CA INDEX NAME)



RN 259103-10-1 CAPLUS
CN Acetamide, N-[2-[[7-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (CA INDEX NAME)



RN 259103-11-2 CAPLUS
CN Acetamide, N-[2-[[7-[[(1R)-1-(hydroxymethyl)-3-methylbutyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 259103-13-4 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-methoxyethyl)-5-[(phenylmethyl)thio]-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 259103-14-5 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2-ethoxyethyl)-5-[(phenylmethyl)thio]-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 259103-15-6 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, N7-(2,2-dimethylpropyl)-5-[(phenylmethyl)thio]-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)



RN 259103-16-7 CAPLUS
CN 1-Pentanol, 4-methyl-2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259103-17-8 CAPLUS
CN 2-Propanol, 1-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-18-9 CAPLUS
CN 1-Butanol, 2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-19-0 CAPLUS
CN 1-Propanol, 2-[[5-[(phenylmethyl)thio]-2-[[2-(2-thienyl)ethyl]amino]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-21-4 CAPLUS
CN 1-Pentanol, 2-[[2-[(2-hydroxyethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259103-24-7 CAPLUS
CN 1-Pentanol, 2-[[2-[(3-hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259103-25-8 CAPLUS
CN 1-Butanol, 2-[[2-[(3-hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-26-9 CAPLUS
CN 1-Propanol, 2-[[2-[(3-hydroxypropyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-28-1 CAPLUS
CN Acetamide, 2-[[7-[(2-hydroxy-1-methylethyl)amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-yl]amino]- (CA INDEX NAME)



RN 259103-32-7 CAPLUS
CN 1-Propanol, 3-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-33-8 CAPLUS
CN 1-Propanol, 2-methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-34-9 CAPLUS
CN 1-Propanol, 2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



RN 259103-35-0 CAPLUS
CN 1-Pentanol, 4-methyl-2-[[2-[[2-(4-morpholinyl)ethyl]amino]-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 259104-23-9 CAPLUS
CN 1-Butanol, 4-[[2-amino-5-[[(2,3-difluorophenyl)methyl]thio]thiazolo[4,5-d]pyrimidin-7-yl]amino]- (CA INDEX NAME)



GI



I



II

AB The title compds. [I; R1 = H, NR3R4 (wherein R3, R4 = H, 4-piperidinyl, alkyl, etc.; NR3R4 = (un)substituted 4-7 membered saturated heterocyclic ring); X = OH, NR13R14 (R13, R14 = H, 4-piperidinyl, etc.; NR13R14 = (un)substituted 4-7 membered saturated heterocyclic ring); R2 = alkyl, alkenyl optionally substituted by (un)substituted Ph or PhO], useful for treating a chemokine mediated disease wherein the chemokine binds to a CXCR2 receptor such as an inflammatory disease (e.g. psoriasis), were prepared Thus, treating 2-amino-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-7(4H)-one with POCl3 and N,N-dimethylaniline followed by reacting the resulting 7-chloro-5-[(phenylmethyl)thio]thiazolo[4,5-d]pyrimidin-2-amine with (R)-2-amino-1-butanol in THF afforded the title thiazolopyrimidine (2R)-II. Exemplified compds. I were found to have IC50 of < 10 μM against hrCXCR2 binding.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:243961 CAPLUS
DOCUMENT NUMBER: 125:10744
TITLE: New synthesis of substituted 4-aminoquinazolines and their hetero analogs
AUTHOR(S): Gewald, K.; Schaefer, H.; Eckert, K.; Jeschke, T.
CORPORATE SOURCE: Inst. Org. Chem., Technischen Univ. Dresden, Dresden, Germany
SOURCE: Journal fuer Praktische Chemie/Chemiker-Zeitung (1996), 338(3), 206-13
CODEN: JPCCEM; ISSN: 0941-1216
PUBLISHER: Barth
DOCUMENT TYPE: Journal
LANGUAGE: German
OTHER SOURCE(S): CASREACT 125:10744
IT 177356-01-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted aminoquinazolines and their hetero analogs)
RN 177356-01-3 CAPLUS
CN Acetamide, 2-[[7-amino-2-[(phenylmethyl)amino]thiazolo[4,5-d]pyrimidin-5-yl]thio]-N-(phenylmethyl)- (CA INDEX NAME)



GI



AB N-(chloroacetyl)anthranilonitrile reacted with KSCN in the presence of EtOH to the quinazolinylthioacetic acid ester I (R = SCH2CO2Et, R1 = H). In the presence of H2O or primary amine the derivs. I (R = SCH2CO2H, SCH2CONHR2) were obtained. Diaminoquinazolines I [R = NR2R3; R1, R2 = CH2Ph, NH2, R3 = H; R1 = H, R2R3 = -(CH2)5-] arose if vigorous reaction conditions are employed. Starting from 2-(chloroacetyl)aminocyclopent-1-enecarbonitrile the pyrimidines II [R = SCH2COR4; R4 = OH, OMe, NHCH2Ph, HNNH2, NH(CH2)2NEt2] were formed with KSCN. Analogously, pyrimidylselenoacetic acid derivs. were prepared with KSeCN. N-chloroacetyl derivs. of 5-membered heterocycles with enaminonitrile structure reacted with KSCN to yield thieno[2,3-d]-, thiazolo[4,5-d]-, pyrrolo[2.3-d]-, furo[2,3-d], and pyrazolo[4,3-d]pyrimidines.

L4 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1971:22787 CAPLUS
DOCUMENT NUMBER: 74:22787
ORIGINAL REFERENCE NO.: 74:3687a,3690a
TITLE: Synthesis of derivatives of thiazolo[4,5-d]pyrimidine. II
AUTHOR(S): Baker, James Albert; Chatfield, P. V.
CORPORATE SOURCE: Sch. Pharm., Brighton Polytech., Moulsecoomb/Brighton, UK
SOURCE: Journal of the Chemical Society [Section] C: Organic (1970), (18), 2478-84
CODEN: JSOOAX; ISSN: 0022-4952
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 30162-34-6P, Acetamide, N-[3-acetyl-2,3-dihydro-2-imino-5-(methylthio)thiazolo[4,5-d]pyrimidin-7-yl]-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 30162-34-6 CAPLUS
CN Acetamide, N-[3-acetyl-2,3-dihydro-2-imino-5-(methylthio)thiazolo[4,5-d]pyrimidin-7-yl]- (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.
AB An attempt to prepare thiazolo[4,5-d]pyrimidine-5,7-diol (I) by the action of KOBr on thiazole-4,5-dicarboxamide revealed the instability of the thiazole portion of this condensed ring system when 2-substituents are lacking. The product obtained was bis(4-amino-2,6-dihydroxypyrimidin-5-yl) disulfide, contrary to an earlier report. Thiazolo[4,5-d]pyrimidines were prepared by cyclization of the corresponding 4-aminopyrimidin-5-yl thiocyanates. Deamination of aminothiazolo[4,5-d]pyrimidines, with nitrous acid, has given a number of derivs. among which is the analog of uric acid.

L4 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1955:84542 CAPLUS
DOCUMENT NUMBER: 49:84542
ORIGINAL REFERENCE NO.: 49:15981g-i,15982a-b
TITLE: 2-Amino-5,7-disubstituted thiazolo(4,5-d)pyrimidines
PATENT ASSIGNEE(S): Wellcome Foundation Ltd.
DOCUMENT TYPE: Patent
LANGUAGE: Unavailable
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 713652		19540818	GB 1951-13173	19510604

IT 30162-03-9P, Thiazolo[4,5-d]pyrimidine, 2,7-diamino-5-(methylthio)-
RL: PREP (Preparation)
(preparation of)
RN 30162-03-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-(methylthio)- (CA INDEX NAME)



GI For diagram(s), see printed CA Issue.
AB The preparation of I is covered, in which R is H, Me, NH2, OH, or ZS (Z = alkyl group containing 1 to 5 C atoms) and R' is NH2, OH, or Me with either R or R' being OH or NH2. To 2,4-diamino-6-methylpyrimidine (12.4 g.) and 40 g. KSCN in 200 ml. 96% AcOH was added in subdued light with ice-cooling and stirring, 6 ml. Br in 100 ml. HOAc, stirred an addnl. 40 min., the temperature was raised to 70°, 50 ml. of H2O added and light admitted to increase the polymerization rate of the excess thiocyanogen (II). The insol. orange polymer of II was filtered from the hot solution, the filtrate cooled in an ice-bath and made alkaline by the addition of concentrated NH4OH. The resulting yellow solid was let stand overnight at 5°. and filtered to yield 10.1 g. 2,5-diamino-7-methylthiazolo-(4,5-d)pyrimidine hydrate, m. 249-50° (from 95% EtOH). In an analogous manner, the following I were prepared from the appropriate pyrimidine (R, R', m.p. given): NH2, Me, >300°; NH2, NH2, >300°; OH, OH, >310°; NH2, MeS, 208-9°; OH, NH2, >310°; NH2, H, 245-7°. Most of these compds. are monohydrates; the H2O of hydration is lost at 140° in vacuo, but is regained upon exposure to air. These compds. are growth-inhibitors for microorganisms, being particularly active for Lactobacillus casei, Bacillus subtilis, Salmponella typhosa, Staphylococcus aureus, and Escherichia coli.

L4 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1952:23490 CAPLUS
DOCUMENT NUMBER: 46:23490
ORIGINAL REFERENCE NO.: 46:4008c-i
TITLE: Condensed pyrimidine systems. VI. Some 2-aminothiazolo[4, 5-d]-pyrimidines
CORPORATE SOURCE: Wellcome Research Labs., Tuckahoe, NY
SOURCE: Journal of the American Chemical Society (1951), 73, 4226-8
CODEN: JACSAT; ISSN: 0002-7863
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
IT 30162-03-9P, Thiazolo[4,5-d]pyrimidine, 2,7-diamino-5-(methylthio)-
RL: PREP (Preparation)
(preparation of)
RN 30162-03-9 CAPLUS
CN Thiazolo[4,5-d]pyrimidine-2,7-diamine, 5-(methylthio)- (CA INDEX NAME)



AB cf. C.A. 45, 8536h. Thiocyanation in the 5-position occurs readily with pyrimidines bearing at least 2 OH or NH2 groups in positions 2, 4, and 6. The 4-amino-5-thiocyanopyrimidines are readily cyclized to 2-aminothiazolo[4, 5-d]pyrimidines. An alternate synthesis of thiazolo[4, 5-d]pyrimidines bearing nonfunctional substituents in the 2- and 4-position was also developed. Two general methods of preparation of thiazolopyrimidines were used: Method A. 2, 4-Diamino-6-methylpyrimidine (12.4 g.) and 40 g. KSCN in 200 cc. 96% AcOH treated with 6 cc. Br in 100 cc. AcOH during 30 min. (ice bath and darkened room), the ice bath removed, the mixture stirred 40 min., heated to 70°, diluted with 50 cc. hot water (lights on), filtered hot, the filtrate (ice bath) slowly made alkaline with concentrated NH4OH, and the product allowed to stand overnight at 5° yielded 10.1 g. 2, 5-diamino-7-methylthiazolo-[4, 5-d]pyrimidine-H2O, m. 249-50° (from EtOH). The hydrates lose water of crystallization after 3 hrs. at 140° in vacuo, but tend to regain it on exposure to air. Method B. POCl3 (100 cc.) and 30 g. 2-ethylmercapto-4-hydroxy-6-methylpyrimidine heated 1 hr. on the steam bath, most of the POCl3 removed in vacuo, 200 g. ice and 200 cc. Et2O added to the oil, then NH4OH to pH 8-9, the Et2O layer added to 100 cc. EtOH containing 17 g. KSCN, the Et2O removed, 100 cc. PhMe added, the solution concentrated to 75°, 100 cc. xylene added, the mixture refluxed 2 hrs., filtered warm, and 20 cc. concentrated NH4OH added to the filtrate yielded 18 g. 2-ethylmercapto-6-methyl-4-thioureidopyrimidine (I), m. 235-6°. Powdered I (4.4 g.) in 20 cc. CHCl3 treated during 15 min. with 1 cc. Br in 10 cc. CHCl3 (temperature below 30°), the solution evaporated to dryness on the steam bath, the residue treated 10 min. with 2 g. Na2S2O4 in 50 cc. water, and the oil treated with excess NH3 yielded 4 g. 2-amino-5-ethylmercapto-7-methylthiazolo[4, 5-d]pyrimidine, m. 187-9° (from 50% EtOH).

2-Amino-4-hydroxy-6-phenylpyrimidine (4.7 g.) and 6.2 g. NaSCN, in 200 cc. warm MeOH saturated with NaBr and 50 cc. AcOH, treated at 5° during 20 min. with 1.8 cc. Br in 50 cc. AcOH, the mixture stirred 1 hr. without an ice bath, heated to boiling, 20 cc. hot water added, the hot solution filtered, brought to pH 6 with 10% NH3, and most of the alc. removed in vacuo yielded 4.1 g. 2-amino-4-hydroxy-6-phenyl-5-thiocyanopyrimidine (II), m. 287-9° (decomposition). II (0.5 g.) in 30 cc. 10% NaOH let stand overnight, diluted to 200 cc., filtered, and the filtrate brought to pH 6 with 10% AcOH yielded 100% bis(2-amino-4-hydroxy-6-phenyl-5-pyrimidyl) disulfide, pale yellow crystalline precipitate, m. above 300°. For the 5-R-7-R'-disubstituted 2-aminothiazolo[4, 5-d]pyrimidines (prepared by Method A), R, R' m.p., yield (%), and recrystn. solvent are: NH2, Me, 249-50°, 52, EtOH; Me, NH2, above 300°, 63, EtOH; NH2, NH2, above 300°, 75, water; OH, OH, above 310°, 45, water; MeS, NH2, 208-9°, 79, 50% EtOH; NH2, OH, above 310°, 72, water; H, NH2, 245-7°, 54, water. Biologically the compds. show several resemblances to other purine analogs.

10575534.trn

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	99.06	278.55

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-14.40	-14.40

STN INTERNATIONAL LOGOFF AT 23:02:35 ON 05 FEB 2008